GlassScriptPhysician profile
Jerry F Sherrill
NPI 1073587390
$4,995.35
in general payments reported to CMS, 2019-2025
52 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $610 · 2021: $12.27 · 2022: $858 · 2023: $684 · 2024: $457 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.94 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Acadia Pharmaceuticals INC | $349.58 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $333.34 | 2019-2022 | |
| Pfizer INC. | $271.58 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $266.85 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $238.53 | 2019-2025 | Uplizna |
| Biogen, INC. | $226.84 | 2019-2022 | |
| Emd Serono, INC. | $181.68 | 2019-2025 | |
| Genzyme Corporation | $181.41 | 2019-2020 | |
| Eisai INC. | $177.10 | 2019-2020 | |
| Allergan, INC. | $153.31 | 2019 | |
| Supernus Pharmaceuticals, INC. | $149.57 | 2019-2020 | |
| Lundbeck LLC | $129.06 | 2020-2025 | Rexulti, Vyepti |
| Alexion Pharmaceuticals, INC. | $112.08 | 2019-2025 | Ultomiris |
| Upsher-Smith Laboratories LLC | $100.82 | 2019-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Sherrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.